Journal of Clinical Oncology
Articles in this Issue
Liver transplantation for unresectable colorectal liver metastases: Pooled real-world data from all Belgian liver transplant centers.
20 Background: Liver transplantation (LTx) for unresectable colorectal liver metastases (uCLM) has gained renewed interest...
Clinico-genomic characterization of <i>TP53</i> / <i>CDKN2A</i> co-alteration and its prognostic value in biliary tract cancer (BTC).
593 Background: TP53 and CDKN2A are the most frequently mutate...
DISCO: Diagnostic performance of <sup>64</sup> Cu-SARTATE compared to <sup>68</sup> Ga-DOTATATE in patients with known or suspected neuroendocrine tumors with focus on liver findings.
618 Background: Diagnostic imaging is critical in the theranostic management of neuroendocrine tumors (NETs)....
Phase I trial of emavusertib (CA-4948) in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated, unresectable gastric and esophageal cancer.
417 Background: Interleukin-1 Receptor Associated Kinase -4 (IRAK4) drives pro-survival NF-kB signaling in various gastroi...
Comparative effectiveness of trastuzumab deruxtecan versus real-world treatment in HER2-amplified advanced solid tumors detected by cell-free DNA: An exploratory analysis of the HERALD trial and GOZILA study.
833 Background: In the phase II basket trial HERALD, trastuzumab deruxtecan (T-DXd) showed favorable clinical outcomes for...
TP53 Y220C mutation in esophageal adenocarcinoma: A genomic landscape study.
442 Background: Although an uncommon variant, the TP53 Y220C base substitution mutation has gained significant attention a...
Phase II trial of neoadjuvant short-course radiotherapy followed by ivonescimab with or without chemotherapy in locally advanced rectal cancer (TRIUNITE-03).
TPS258 Background: Despite significant advances in combining immune checkpoint inhibitors with chemoradiotherapy for local...
Risk factors for early-onset colorectal cancer in the United States: An epidemiologic investigation.
92 Background: The rising incidence of colorectal cancer (CRC) in younger adults is a growing public health concern in the...
Sequencing fruquintinib and trifluridine/tipiracil to improve outcomes in the real-world management of MMR-proficient, chemo-refractory colorectal cancer in Hong Kong.
173 Background: The optimal treatment sequence of chemo-refractory MMR-proficient colorectal cancers (CRC) is unknown. Tri...
Amivantamab plus FOLFOX or FOLFIRI in <i>RAS/BRAF</i> wild-type metastatic colorectal cancer: Long-term follow-up from the phase 1b/2 OrigAMI-1 study.
166 Background: Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity that has demonstr...
Racial and ethnical disparities in treatment outcomes in patients with advanced HCC who received first-line immunotherapy.
488 Background: Advancements in immunotherapy (IO) and targeted therapy have shown tremendous improvement in survival outc...
Evaluating the correlation between clonal hematopoiesis and response to regorafenib and nivolumab in patients with refractory metastatic colorectal cancer.
133 Background: Clonal hematopoiesis (CH) has emerged as a possible biomarker of immune modulation in cancer. Preliminary...
Characterization of LAT1-related gene expression and its impact on prognostic tumor mutations and gastrointestinal (GI) cancer clinical outcomes.
849 Background: Expression of the L-type amino acid transporter 1 (LAT1; gene symbol: SLC7A5...
Deep learning–based cfDNA fragment–level analysis: A genome-scanning approach for detection of colorectal cancer.
243 Background: Cell-free DNA (cfDNA) is a promising biomarker for cancer detection. Circulating tumor DNA (ctDNA) in canc...
Effect of therapeutic targeting of xCT on USP15/SMAD-driven gemcitabine resistance in KRAS-mutant pancreatic cancer.
763 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, characterized by poor prog...
Circulating tumor DNA profiling and its association with clinical outcomes in metastatic colorectal cancer: Insights from the FRESCO-2 study.
199 Background: Fruquintinib is a highly selective, oral inhibitor of all 3 vascular endothelial growth factor receptors....
Italian prospective observational RealFLOT study: Four-year update.
370 Background: For patients (pts) with resectable gastric or gastroesophageal junction adenocarcinoma who are candidates...
Detecting <i>MTAP</i> loss in liquid biopsies from patients with pancreatic ductal adenocarcinoma.
766 Background: MTAP loss is an emerging biomarker guiding investigational use of PRMT5 and MAT2A inhi...
Real-world patient-reported outcomes in stage II/III rectal cancer in the Netherlands.
65 Background: In a real-world (RW) study, tumor characteristics and outcomes differed between patients (pts) with mismatc...
Survival outcomes of first-line anti-EGFR antibody versus anti-VEGF therapy stratified by DNA methylation status in right-sided metastatic colorectal cancer: A propensity score weighting analysis.
156 Background: The clinical benefit of anti-EGFR antibodies (anti-EGFR ab) is generally limited in right-sided metastatic...
Chemo-immunotherapy sequential with radiotherapy and immunotherapy consolidation in patients with advanced or metastatic esophageal squamous cell carcinoma.
342 Background: This study was to evaluate the efficacy and safety of chemo-immunotherapy combined with residual lesions i...
A prospective, single-arm phase II study of trilaciclib combined with immunotherapy and chemotherapy as first-line treatment for metastatic/recurrent esophageal squamous cell carcinoma.
411 Background: Immunotherapy combined with chemotherapy has become the first-line treatment for advanced esophageal squam...
MTAP loss in anal melanoma: A genomic landscape study.
4 Background: Anal melanoma (AM) is a rare, highly aggressive malignancy with poor prognosis, and thus further exploration...
Neoadjuvant chemoradiotherapy versus chemotherapy alone for locally advanced esophageal adenocarcinoma: A National Cancer Database analysis.
302 Background: The optimal neoadjuvant strategy for resectable, locally advanced esophageal adenocarcinoma (EAC) remains...
Decreasing hypoxia with mitochondrial inhibition in locally advanced rectal cancer: Phase 1 trial of papaverine in combination with radiation (DINOMITE).
TPS274 Background: Surgical resection of locally advanced rectal cancer (LARC) can be morbid with debilitating effects on...